Answers are grounded in this paper and cite their sources.
Clinical trial shows longer survival and reduced toxicity after CD19 CAR T-cell therapy in low-burden acute lymphoblastic leukemia, highlighting the benefit of earlier treatment.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Park et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: